1.Shanbhag S, Ambinder RF: Hodgkin lymphoma: A review and update on recent progress. CA: a cancer journal for clinicians 2018, 68(2):116–132.
2.Townsend W, Linch D: Hodgkin’s lymphoma in adults. The Lancet 2012, 380(9844):836–847.
3.Mottok A, Steidl C: Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 2018.
4.Guerard EJ, Bishop MR: Overview of non-Hodgkin’s lymphoma. Dis Mon 2012, 58(4):208–218.
5.Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE et al: Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol 2014, 93(4):541–556.
6.Shah BD, Martin P, Sotomayor EM: Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control 2012, 19(3):227–235.
7.Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin lymphoma. The Lancet 2012, 380(9844):848–857.
8.Furtado M, Rule S: Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin. Clin Med Insights Oncol 2012, 6:31–39.
9.June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC: CAR T cell immunotherapy for human cancer. Science 2018, 359(6382):1361–1365.
10.Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD et al: Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. The New England journal of medicine 2010, 362(10):875–885.
11.Van Loo P, Tousseyn T, Vanhentenrijk V, Dierickx D, Malecka A, Vanden Bempt I, Verhoef G, Delabie J, Marynen P, Matthys P et al: T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 2010, 95(3):440–448.
12.Hartmann S, Doring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, Sagaert X, Ponzoni M, Facchetti F, de Wolf-Peeters C et al: Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma—endpoints of a spectrum of one disease? PloS one 2013, 8(11):e78812.
13.Hotamisligil GS: Inflammation, metaflammation and immunometabolic disorders. Nature 2017, 542(7640):177–185.
14.Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T et al: Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009, 113(12):2765–3775.
15.Linton K, Howarth C, Wappett M, Newton G, Lachel C, Iqbal J, Pepper S, Byers R, Chan WJ, Radford J: Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. J Mol Diagn 2012, 14(3):223–232.
16.Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L et al: Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma. Blood 2016, 128(1):82–92.
17.Taub DD: Cytokine, growth factor, and chemokine ligand database. Curr Protoc Immunol 2004, Chapter 6:Unit 6 29.
18.Cameron MJ, Kelvin JJ: Cytokines, chemokines and their receptors. Madame Curie Database http://wwwncbinlmnihgov/books/NBK6294/ 2013.
19.Carvalho BS, Irizarry RA: A framework for oligonucleotide microarray preprocessing. Bioinformatics 2010, 26(19):2363–2367.
20.Li WX, Dai SX, Liu JQ, Wang Q, Li GH, Huang JF: Integrated Analysis of Alzheimer’s Disease and Schizophrenia Dataset Revealed Different Expression Pattern in Learning and Memory. Journal of Alzheimer’s disease: JAD 2016, 51(2):417–425.
21.Li WX, Dai SX, Wang Q, Guo YC, Hong Y, Zheng JJ, Liu JQ, Liu D, Li GH, Huang JF: Integrated analysis of ischemic stroke datasets revealed sex and age difference in anti-stroke targets. PeerJ 2016, 4:e2470.
22.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research 2015, 43(7):e47.
23.Liu HY, Zhao H, Li WX: Integrated Analysis of Transcriptome and Prognosis Data Identifies FGF22 as a Prognostic Marker of Lung Adenocarcinoma. Technol Cancer Res Treat 2019, 18:1533033819827317.
24.Maere S, Heymans K, Kuiper M: BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005, 21(16):3448–3449.
25.Zuberi K, Franz M, Rodriguez H, Montojo J, Lopes CT, Bader GD, Morris Q: GeneMANIA prediction server 2013 update. Nucleic acids research 2013, 41(Web Server issue):W115–122.
26.Liu F, Zhang G, Liu F, Zhou X, Chen X, Han X, Wu Z, Zhao T: Effect of shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in vitro and in vivo. Oncol Rep 2013, 29(4):1405–1414.
27.Girish V, Vijayalakshmi A: Affordable image analysis using NIH Image/ImageJ. Indian J Cancer 2004, 41(1):47.
28.Brockelmann PJ, Engert A: Checkpoint Inhibition in Hodgkin Lymphoma - a Review. Oncol Res Treat 2017, 40(11):654–660.
29.Avanzi MP, Brentjens RJ: Emerging Role of CAR T Cells in Non-Hodgkin’s Lymphoma. J Natl Compr Canc Netw 2017, 15(11):1429–1437.
30.Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, Lokshin AE, Zeleniuch-Jacquotte A: Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer causes & control: CCC 2010, 21(8):1323–1333.
31.Paradisi R, Vicenti R, Macciocca M, Seracchioli R, Rossi S, Fabbri R: High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma. Fertility and sterility 2016, 106(5):1176–1182.
32.Zhou Q, Huang L, Gu Y, Lu H, Feng Z: The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research. Cancer Biomark 2018, 21(4):925–934.
33.Corcione A, Arduino N, Ferretti E, Raffaghello L, Roncella S, Rossi D, Fedeli F, Ottonello L, Trentin L, Dallegri F et al: CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clinical cancer research: an official journal of the American Association for Cancer Research 2004, 10(3):964–971.
34.Chiu J, Ernst DM, Keating A: Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Front Immunol 2018, 9:267.
35.Maruoka H, Inoue D, Takiuchi Y, Nagano S, Arima H, Tabata S, Matsushita A, Ishikawa T, Oita T, Takahashi T: IP–10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol 2014, 93(3):393–401.
36.Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E: CXCL13 and CXCL12 in central nervous system lymphoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15(19):5968–5973.
37.Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M et al: CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 2013, 121(23):4740–4748.
38.Lu J, Chatterjee M, Schmid H, Beck S, Gawaz M: CXCL14 as an emerging immune and inflammatory modulator. Journal of Inflammation 2016, 13(1).
39.Chang AH, Raftrey BC, D’Amato G, Surya VN, Poduri A, Chen HI, Goldstone AB, Woo J, Fuller GG, Dunn AR et al: DACH1 stimulates shear stress-guided endothelial cell migration and coronary artery growth through the CXCL12-CXCR4 signaling axis. Genes Dev 2017, 31(13):1308–1324.
40.Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH: Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma. Vet Comp Oncol 2017, 15(2):315–327.
41.Otte M, Kliewer A, Schutz D, Reimann C, Schulz S, Stumm R: CXCL14 is no direct modulator of CXCR4. FEBS letters 2014, 588(24):4769–4775.
42.Kojiro-Sanada S, Yasuda K, Nishio S, Ogasawara S, Akiba J, Ushijima K, Yano H: CXCL14-CXCR4 and CXCL12-CXCR4 Axes May Play Important Roles in the Unique Invasion Process of Endometrioid Carcinoma With MELF-Pattern Myoinvasion. Int J Gynecol Pathol 2017, 36(6):530–539.
43.Collins PJ, McCully ML, Martinez-Munoz L, Santiago C, Wheeldon J, Caucheteux S, Thelen S, Cecchinato V, Laufer JM, Purvanov V et al: Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4. FASEB J 2017, 31(7):3084–3097.
44.Di Napoli A, De Cecco L, Piccaluga PP, Navari M, Cancila V, Cippitelli C, Pepe G, Lopez G, Monardo F, Bianchi A et al: Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. Mod Pathol 2019, 32(2):216–230.
45.Ji X, Shen Z, Zhao B, Yuan X, Zhu X: CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection. Medicine 2018, 97(10):e0101.